Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
Authors:
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 27 (8) , 1124-1130
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Ministere de la Sante et des Solidarites
- Ministère des Solidarités et de la Santé
- Regional Council of Pays de la Loire
- Angers Loire Métropole
This publication has 21 references indexed in Scilit:
- “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance CentersTherapies, 2020
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York StateJAMA, 2020
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19New England Journal of Medicine, 2020
- 硫酸羟氯喹治疗2019冠状病毒病(COVID-19)普通型患者的初步研究2020
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialBMJ, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort studyBMJ, 2020
- Temporal dynamics in viral shedding and transmissibility of COVID-19Nature Medicine, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020